X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time
https://www.globenewswire.com//news-release/2024/02/22/2833513/32445/en/Minerva-Neurosciences-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results-and-Business-Updates.html
https://www.globenewswire.com//news-release/2023/11/07/2774981/32445/en/Minerva-Neurosciences-Reports-2023-Third-Quarter-Financial-Results-and-Business-Updates.html
https://www.globenewswire.com/news-release/2023/08/01/2715716/32445/en/Minerva-Neurosciences-Reports-2023-Second-Quarter-Financial-Results-and-Business-Updates.html
https://www.globenewswire.com/news-release/2023/06/28/2696167/32445/en/Minerva-Neurosciences-Announces-20-Million-in-Private-Placement-Priced-at-a-Premium-to-Market.html
https://www.globenewswire.com/news-release/2023/05/15/2668650/32445/en/Minerva-Neurosciences-Reports-2023-First-Quarter-Financial-Results-and-Business-Updates.html
https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/05/08/2663294/32445/en/Minerva-Neurosciences-to-Report-First-Quarter-2023-Financial-Results-and-Business-Updates-on-May-15-2023.html
https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
https://www.globenewswire.com/news-release/2023/03/08/2622920/32445/en/Minerva-Neurosciences-Reports-Fiscal-Year-2022-Fourth-Quarter-And-Year-End-Financial-Results-And-Business-Updates.html
Market Place
Share 
